Innovative AI-based Ophthalmologic Diagnosis

Informations projet

aiVision

N° de convention de subvention: 886575

DOI

10.3030/886575

Projet clôturé

Date de signature de la CE 22 Novembre 2019

Date de début 1 Decembre 2019

Date de fin 31 Mars 2020

Financé au titre de

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Coût total

€ 71 429,00

Contribution de l’UE

€ 50 000,00

Coordonné par

AISCREENINGS
France

Periodic Reporting for period 1 - aiVision (Innovative AI-based Ophthalmologic Diagnosis)

Période du rapport: 2019-12-01 au 2020-03-31

Résumé du contexte et des objectifs généraux du projet

AiVision is a unique telemedicine cloud solution powered by deep learning AI that supports the diagnosis of sight related diseases. It is created with the objective of optimizing the detection and treatment of a highly probable cause of blindness.
Its initial indication targets Diabetic Retinopathy the leading cause of blindness affecting the Diabetic population less than 65 years old. After 15 years of treating diabetes, 95% of type 1 diabetic patients and 60% of type 2 diabetic patients suffer from at least a mild and in some cases from severe diabetic retinopathy. In 2015, 415m people suffered from diabetes and this figure will grow up to 640m in 2040. There are 34,2M diabetics in the US, and around 24,000 new cases per year of retinopathy due to diabetes.
aiVision intends to solve ophthalmologic Patient Journey through an improved eye screening medical examination process facilitated by a telemedicine platform and automated algorithms that support diagnosis decision making.
The objectives of the feasibility study were to assess in depth the target markets and segments, technology benchmark, financial projections and overall business assessment.

Travail effectué depuis le début du projet jusqu’à la fin de la période considérée dans le rapport et principaux résultats atteints jusqu’à présent

During the Feasibility study, we assessed in detail our business plan. On the technology side, we established a regulatory and development roadmap for our target markets. For the business, we reviewed our market assumptions, updated our sources and improved our knowledge of specific segments. We also established a go-to-market strategy and identified key stakeholders for our target markets.
Internally, we have re-evaluated our IPR strategy and risk management, and the company’s HR needs for the next 2 years according to our new updated business plan.

Progrès au-delà de l’état des connaissances et impact potentiel prévu (y compris l’impact socio-économique et les conséquences sociétales plus larges du projet jusqu’à présent)

The Feasibility Study contributed significantly to increase our knowledge and accurate identification of key requirements (business, technical, regulatory, financial, etc.) to grow our business beyond our home markets.
With our federated approach to AI screening, we focus on the protection of patient data, and at the same time enable a revolution in Ophthalmologic Remote Patient Diagnosis. The overall uptake of aiVision will bring substantial gains to society, by making preventive screening available to more end-users at a lower cost, facilitate the results of eye screening exams and encourage a better follow-up of patients.

logo